DRL gears up for biosimilar push, consumer health growth post record FY25
Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launches, and semaglutide portfolio support long-term prospects despite Revlimid taper and reduced target prices by (...)
Site référencé: The Economic Times
The Economic Times
Sebi proposes allowing investment advisers, analysts to use liquid MFs for deposit requirements
9/05/2025
Birla Corporation Q4 Results : Cons PAT rises 32% to Rs 256 crore
9/05/2025
Manappuram posts Rs 203 crore loss on Asirvad stress, names new CEO
9/05/2025
Cholamandalam Financial Holdings report consolidated Q4 PAT at Rs 1,362.18 cr
9/05/2025
Sebi mulls tweaking disclosure format for corporate governance framework by HVDLEs
9/05/2025
Dr Reddy's Labs Q4 Results : Cons PAT jumps 22% to Rs 1,594 crore ; Rs 8 per share dividend announced
9/05/2025
